BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression

• Published in: NPJ breast cancer Vol. 6; no. 1; p. 12
• Main Authors: Elsarraj, Hanan S., Hong, Yan, Limback, Darlene, Zhao, Ruonan, Berger, Jenna, Bishop, Stephanie C., Sabbagh, Aria, Oppenheimer, Linzi, Harper, Haleigh E., Tsimelzon, Anna, Huang, Shixia, Hilsenbeck, Susan G., Edwards, Dean P., Fontes, Joseph, Fan, Fang, Madan, Rashna, Fangman, Ben, Ellis, Ashley, Tawfik, Ossama, Persons, Diane L., Fields, Timothy, Godwin, Andrew K., Hagan, Christy R., Swenson-Fields, Katherine, Coarfa, Cristian, Thompson, Jeffrey, Behbod, Fariba
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 24.04.2020; Nature Publishing Group
• Subjects: 631/67/1347; 631/67/2195; Biology; Biomarkers; Biomedical and Life Sciences; Biomedicine; Breast cancer; Cancer Research; Cell Biology; DNA methylation; Human Genetics; Laboratories; Medical research; Medicine; Oncology; Pathology; Protein expression; Proteins; Regulation; Cancer prevention; Breast cancer
• ISSN: 2374-4677; 2374-4677
• DOI: 10.1038/s41523-020-0157-z

The molecular processes by which some human ductal carcinoma in situ (DCIS) lesions advance to the more aggressive form, while others remain indolent, are largely unknown. Experiments utilizing a patient-derived (PDX) DCIS Mouse INtraDuctal (MIND) animal model combined with ChIP-exo and RNA sequencing revealed that the formation of protein complexes between B Cell Lymphoma-9 (BCL9), phosphoserine 727 STAT3 (PS-727-STAT3) and non-STAT3 transcription factors on chromatin enhancers lead to subsequent transcription of key drivers of DCIS malignancy. Downregulation of two such targets, integrin β3 and its associated metalloproteinase, MMP16, resulted in a significant inhibition of DCIS invasive progression. Finally, in vivo targeting of BCL9, using rosemary extract, resulted in significant inhibition of DCIS malignancy in both cell line and PDX DCIS MIND animal models. As such, our studies provide compelling evidence for future testing of rosemary extract as a chemopreventive agent in breast cancer.